帕博利珠单抗治疗程序性死亡配体1阳性晚期卵巢癌:KEYNOTE-028分析
多队列Ib期KEYNOTE-028 trial纳入26例PD-L1阳性晚期卵巢癌患者,接受帕博利珠单抗10 mg/kg每2周治疗。中位随访15.4个月后,确认客观缓解率为11.5%(1例完全缓解,2例部分缓解),7例(26.9%)疾病稳定;中位无进展生存期1.9个月(95%CI 1.8-3.5),中位总生存期13.8个月(95%CI 6.7-18.8)。
要点
- 26例PD-L1阳性晚期卵巢癌患者接受帕博利珠单抗10 mg/kg每2周治疗,确认ORR为11.5%。
- 治疗相关不良事件发生率为73.1%,1例3级治疗相关不良事件(血浆转氨酶升高)。
- 中位无进展生存期1.9个月(95%CI 1.8-3.5),中位总生存期13.8个月(95%CI 6.7-18.8)。
核心结论
- 帕博利珠单抗在晚期PD-L1阳性卵巢癌患者中 confer 持久抗肿瘤活性,安全性和毒性可控,正在进行的II期KEYNOTE-100 trial中进一步研究。
研究设计与样本
- 多队列Ib期KEYNOTE-028 trial,纳入26例PD-L1阳性晚期卵巢上皮癌、输卵管癌或原发性腹膜癌患者,既往治疗失败。
- 患者接受帕博利珠单抗10 mg/kg每2周,最长24个月或至疾病进展/不可耐受毒性。
- 主要终点为按RECIST v1.1(研究者评估)确认的客观缓解率,数据截止日期为2017年2月20日。
主要发现
- 26例患者中位年龄57.5岁,38.5%有转移性疾病,73.1%既往接受≥3线治疗。
- 治疗相关不良事件发生于19例(73.1%),最常见为关节痛(19.2%)、恶心(15.4%)和瘙痒(15.4%)。
- 1例3级治疗相关不良事件(血浆转氨酶升高),无死亡和治疗相关不良事件导致的治疗中止。
- 中位随访15.4个月后,确认客观缓解率为11.5%(1例完全缓解,2例部分缓解),7例(26.9%)疾病稳定。
- 中位无进展生存期1.9个月(95%CI 1.8-3.5),中位总生存期13.8个月(95%CI 6.7-18.8)。
关键数值与推荐
- 帕博利珠单抗10 mg/kg每2周,最长24个月或至疾病进展/不可耐受毒性。
- 主要终点为按RECIST v1.1(研究者评估)确认的客观缓解率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate safety, tolerability, and antitumor activity of pembrolizumab monotherapy in patients with programmed death ligand 1 (PD-L1)-expressing advanced ovarian cancer enrolled in the multicohort, phase Ib KEYNOTE-028 trial. METHODS: Key inclusion criteria were age ≥18 years; advanced ovarian epithelial, fallopian tube, or primary peritoneal carcinoma; failure of previous therapy; and tumor PD-L1 positivity. Patients received pembrolizumab (10 mg/kg every 2 weeks) for ≤24 months or until disease progression/intolerable toxicity. Tumor response was assessed per RECIST v1.1 (investigator review). Adverse events (AEs) were graded using CTCAE version 4.0. Primary end point was confirmed objective response rate (ORR) per RECIST v1.1 (investigator review); data cutoff date was February 20, 2017. RESULTS: Twenty-six patients (median age, 57.5 years) with PD-L1-positive advanced metastatic ovarian cancer received pembrolizumab; 38.5% had metastatic disease, and 73.1% previously received ≥3 lines of therapy. Treatment-related AEs (TRAEs) occurred in 19 (73.1%) patients, most commonly arthralgia (19.2%), nausea (15.4%), and pruritus (15.4%). One grade 3 TRAE (increased plasma transaminase level) occurred. No deaths and no treatment discontinuations due to TRAEs occurred. After a median follow-up duration of 15.4 months, ORR was 11.5% (1 complete response, 2 partial responses); 7 patients (26.9%) achieved stable disease. Median progression-free and overall survival were 1.9 (95% CI, 1.8-3.5) and 13.8 (95% CI, 6.7-18.8) months, respectively. CONCLUSION: Pembrolizumab conferred durable antitumor activity with manageable safety and toxicity in patients with advanced PD-L1-positive ovarian cancer and is under further investigation in an ongoing phase II trial, KEYNOTE-100.
引用
- Varga A, Piha-Paul S, Ott PA, et al. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028. Gynecol Oncol. 2018. PMID: 30522700. doi:10.1016/j.ygyno.2018.11.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。